×

• English

  • हिंदी
  • ગુજરાતી
• Home
• My Feed
• Remove AdsGet Premium Content Go Pro @₹99
• Credit Cards
• Instant LoansApply Now
• Credit Score
• Refer & Earn ₹500Refer Now
• Finance Tracker
• Learning Curve
• Fixed Deposits
• Business Loan

• Markets

  • Markets FII & DII Activity
  • Corporate Action Research Advice
  • Earnings Technical Trends
  • Stock Deals Intraday Large Deals
  • Bonds Webinar
  • Pre Market Stock Scanner
  • Sector Analysis Unlisted Shares
  • Stock Updates PRO Stock Lists
• Monsoon Tracker
• Seasonality Analysis
• Crypto Dashboard
• Web Stories
• Tax Calculator
• Forum
• Gold Rate
• Silver Rate
• IFSC Code Finder
• Storyboard18
• IPO
• Economic Indicators
• Economic Calendar
• Global Markets
• US Markets
• ETFs
• Indian Indices

• News

  • News Tech/Startups
  • Auto Research
  • Opinion Politics
  • Personal Finance EPF Guide
• Real Estate
• Portfolio
• Watchlist

• Personal Finance

  • Personal Finance Loans
  • Fixed Deposit Comparison Fixed Deposit Interest Calculator
• Moneycontrol - SecureNow Health Insurance ratings

• Mutual Funds

  • Mutual Funds Performance Tracker
  • Top ranked funds My Portfolio
  • Top performing Categories Forum
  • New Fund Offers MF Simplified

• Commodities

  • Mutual Funds Gold Rate
  • Silver Rate
• Currencies
• Cryptocurrency

• Media

  • Live TV & Shows Video
  • Podcast Photos

• Invest Now

  • Trade like Experts Invest in Unlisted Shares

• Specials

  • Pharma Industry Conclave Unlocking opportunities in Metal and Mining
  • #MFSummit2025 Moneycontrol mutual fund summit 2025
  • Advanced Technical Charts
• International

Weight-Loss Drug Sales Forecast To Hit $150 Billion By 2030 | Wegovy & Zepbound Lead The Charge

Healthcare analysts project a 50% increase in annual sales for weight-loss drugs, estimating a market value of $150 billion by the early 2030s. Key players include Novo Nordisk’s Wegovy and Eli Lilly’s Zepbound, which have captured widespread interest despite limited insurance coverage. Analysts note these drugs could soon be covered by insurers due to their potential in preventing costly health emergencies. Despite 2023 shortages, increased production is underway. Shares in Lilly and Novo have surged, reflecting their growing market dominance. Discover the future of obesity treatment with 80 experimental drugs in the pipeline.

• Home
• Markets
• Loans
• SPIN2WIN
• News
• Portfolio

Follow Us On:

News

more

Business New Market New Stocks Income Tax Calculator Election Schedule 2024 India News Economy Mutual Funds Personal Finance IPO News Startups New USA Elections New

Features

more

Gold Rate Today Silver Rate Today Trending News Startups New National News MC Videos MC You Tube

Tools

more

SIP Calculator 2 SIP Calculator 3 SIP Calculator 1 New SIP Calculator 4

Specials

more

PowerYourTrade Master Your Money Game Changers

Network 18 Sites

more

News18 Firstpost CNN News18 CNBC TV18 Forbes History TV18

Personal Finance

more

Home Loans up to 50 Lakhs Credit Cards Lifetime Free Finance Tracker Fixed Deposits Fixed Deposit Comparison Fixed Income Account Aggregator

Quick Links

more

About Us New Contact Us Advisory Alert New Advertise with Us New Disclaimer Privacy Policy Cookie Policy Terms & Conditions Careers Financial Terms (Glossary) Analytical & Information Tool New

Download MC Apps:

Copyright © Network18 Media & Investments Limited. All rights reserved. Reproduction of news articles, photos, videos or any other content in whole or in part in any form or medium without express written permission of moneycontrol.com is prohibited.